Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC)

Lawrence D. Recht, Michael Glantz, Patricia Meitner, Lisa Glantz, Wallace Akerley, Lars Wahlberg, Stephen Saris, Bernard F. Cole

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To individually tailor chemotherapy for patients with malignant gliomas according to tumor chemosensitivity, a rapid assay system which can be performed with a high success rate is needed. The fluorescent cytoprint assay (FCA) can assess multiple chemotherapeutic agents using small (≃ 500 cells) tumor aggregates very quickly (≡ 1 wk). Tissue samples from 51 patients with malignant gliomas obtained either at time of initial diagnosis (n = 34) or at recurrence were assayed using this method. The assay success rate approached 90% in those culture samples which were histologically verified as tumor. A meaningful number of agents could be tested both on samples obtained by stereotactic biopsy (median, 5) and on specimens from more extensive resections (median, 6). One hundred ninety-three FCAs were performed on a samples obtained from 36 patients. In only twenty six assays (14%) was an agent deemed sensitive (> 90% cell kill) to a chemotherapeutic agent. Sixty-two percent of sensitive FCAs were observed in tumors tested against the activated analog of cyclophosphamide, 4-hydroxyperoxycyclophosphamide (4-HC), where a sensitivity rate (samples sensitive/total tested against agent) of 64% (95% CI, 36.6-77.9%) was noted. This rate was significantly higher than with any other agent tested (p = 0.012, two sided McNemar's test) and was not affected by age, histology or disease status. We conclude that: (1) the FCA represents a feasible method for quickly assaying tumors for sensitivity to multiple chemotherapeutic agents; and (ii) malignant gliomas may be particularly sensitive to 4-HC.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalJournal of neuro-oncology
Volume36
Issue number3
StatePublished - Feb 26 1998

Fingerprint

Glioma
Neoplasms
Cyclophosphamide
Histology
4-hydroxyperoxycyclophosphamide
In Vitro Techniques
Biopsy
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Recht, L. D., Glantz, M., Meitner, P., Glantz, L., Akerley, W., Wahlberg, L., ... Cole, B. F. (1998). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). Journal of neuro-oncology, 36(3), 201-208.
Recht, Lawrence D. ; Glantz, Michael ; Meitner, Patricia ; Glantz, Lisa ; Akerley, Wallace ; Wahlberg, Lars ; Saris, Stephen ; Cole, Bernard F. / Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). In: Journal of neuro-oncology. 1998 ; Vol. 36, No. 3. pp. 201-208.
@article{531dd8e8d5dc43828344d6cb4f2643f6,
title = "Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC)",
abstract = "To individually tailor chemotherapy for patients with malignant gliomas according to tumor chemosensitivity, a rapid assay system which can be performed with a high success rate is needed. The fluorescent cytoprint assay (FCA) can assess multiple chemotherapeutic agents using small (≃ 500 cells) tumor aggregates very quickly (≡ 1 wk). Tissue samples from 51 patients with malignant gliomas obtained either at time of initial diagnosis (n = 34) or at recurrence were assayed using this method. The assay success rate approached 90{\%} in those culture samples which were histologically verified as tumor. A meaningful number of agents could be tested both on samples obtained by stereotactic biopsy (median, 5) and on specimens from more extensive resections (median, 6). One hundred ninety-three FCAs were performed on a samples obtained from 36 patients. In only twenty six assays (14{\%}) was an agent deemed sensitive (> 90{\%} cell kill) to a chemotherapeutic agent. Sixty-two percent of sensitive FCAs were observed in tumors tested against the activated analog of cyclophosphamide, 4-hydroxyperoxycyclophosphamide (4-HC), where a sensitivity rate (samples sensitive/total tested against agent) of 64{\%} (95{\%} CI, 36.6-77.9{\%}) was noted. This rate was significantly higher than with any other agent tested (p = 0.012, two sided McNemar's test) and was not affected by age, histology or disease status. We conclude that: (1) the FCA represents a feasible method for quickly assaying tumors for sensitivity to multiple chemotherapeutic agents; and (ii) malignant gliomas may be particularly sensitive to 4-HC.",
author = "Recht, {Lawrence D.} and Michael Glantz and Patricia Meitner and Lisa Glantz and Wallace Akerley and Lars Wahlberg and Stephen Saris and Cole, {Bernard F.}",
year = "1998",
month = "2",
day = "26",
language = "English (US)",
volume = "36",
pages = "201--208",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Recht, LD, Glantz, M, Meitner, P, Glantz, L, Akerley, W, Wahlberg, L, Saris, S & Cole, BF 1998, 'Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC)', Journal of neuro-oncology, vol. 36, no. 3, pp. 201-208.

Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). / Recht, Lawrence D.; Glantz, Michael; Meitner, Patricia; Glantz, Lisa; Akerley, Wallace; Wahlberg, Lars; Saris, Stephen; Cole, Bernard F.

In: Journal of neuro-oncology, Vol. 36, No. 3, 26.02.1998, p. 201-208.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC)

AU - Recht, Lawrence D.

AU - Glantz, Michael

AU - Meitner, Patricia

AU - Glantz, Lisa

AU - Akerley, Wallace

AU - Wahlberg, Lars

AU - Saris, Stephen

AU - Cole, Bernard F.

PY - 1998/2/26

Y1 - 1998/2/26

N2 - To individually tailor chemotherapy for patients with malignant gliomas according to tumor chemosensitivity, a rapid assay system which can be performed with a high success rate is needed. The fluorescent cytoprint assay (FCA) can assess multiple chemotherapeutic agents using small (≃ 500 cells) tumor aggregates very quickly (≡ 1 wk). Tissue samples from 51 patients with malignant gliomas obtained either at time of initial diagnosis (n = 34) or at recurrence were assayed using this method. The assay success rate approached 90% in those culture samples which were histologically verified as tumor. A meaningful number of agents could be tested both on samples obtained by stereotactic biopsy (median, 5) and on specimens from more extensive resections (median, 6). One hundred ninety-three FCAs were performed on a samples obtained from 36 patients. In only twenty six assays (14%) was an agent deemed sensitive (> 90% cell kill) to a chemotherapeutic agent. Sixty-two percent of sensitive FCAs were observed in tumors tested against the activated analog of cyclophosphamide, 4-hydroxyperoxycyclophosphamide (4-HC), where a sensitivity rate (samples sensitive/total tested against agent) of 64% (95% CI, 36.6-77.9%) was noted. This rate was significantly higher than with any other agent tested (p = 0.012, two sided McNemar's test) and was not affected by age, histology or disease status. We conclude that: (1) the FCA represents a feasible method for quickly assaying tumors for sensitivity to multiple chemotherapeutic agents; and (ii) malignant gliomas may be particularly sensitive to 4-HC.

AB - To individually tailor chemotherapy for patients with malignant gliomas according to tumor chemosensitivity, a rapid assay system which can be performed with a high success rate is needed. The fluorescent cytoprint assay (FCA) can assess multiple chemotherapeutic agents using small (≃ 500 cells) tumor aggregates very quickly (≡ 1 wk). Tissue samples from 51 patients with malignant gliomas obtained either at time of initial diagnosis (n = 34) or at recurrence were assayed using this method. The assay success rate approached 90% in those culture samples which were histologically verified as tumor. A meaningful number of agents could be tested both on samples obtained by stereotactic biopsy (median, 5) and on specimens from more extensive resections (median, 6). One hundred ninety-three FCAs were performed on a samples obtained from 36 patients. In only twenty six assays (14%) was an agent deemed sensitive (> 90% cell kill) to a chemotherapeutic agent. Sixty-two percent of sensitive FCAs were observed in tumors tested against the activated analog of cyclophosphamide, 4-hydroxyperoxycyclophosphamide (4-HC), where a sensitivity rate (samples sensitive/total tested against agent) of 64% (95% CI, 36.6-77.9%) was noted. This rate was significantly higher than with any other agent tested (p = 0.012, two sided McNemar's test) and was not affected by age, histology or disease status. We conclude that: (1) the FCA represents a feasible method for quickly assaying tumors for sensitivity to multiple chemotherapeutic agents; and (ii) malignant gliomas may be particularly sensitive to 4-HC.

UR - http://www.scopus.com/inward/record.url?scp=0031908766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031908766&partnerID=8YFLogxK

M3 - Article

C2 - 9524098

AN - SCOPUS:0031908766

VL - 36

SP - 201

EP - 208

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -

Recht LD, Glantz M, Meitner P, Glantz L, Akerley W, Wahlberg L et al. Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). Journal of neuro-oncology. 1998 Feb 26;36(3):201-208.